Literature DB >> 22473704

HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells.

Clarissa Anni Wild1, Christoph Bergmann, Günter Fritz, Patrick Schuler, Thomas K Hoffmann, Ramin Lotfi, Astrid Westendorf, Sven Brandau, Stephan Lang.   

Abstract

OBJECTIVE: The high-mobility group box-1 protein (HMGB1) serves as the prototypic damage-associated molecular pattern molecule, interacting with a variety of defined pattern recognition receptors in the microenvironment of damaged or necrotic tissue. As regulatory T cells (T(reg)) play a crucial role in autoimmune diseases and tumor immune escape, the previously unexamined role of HMGB1 on the function of T(reg) is of great interest.
METHODS: Human CD4(+)CD25(+)CD127(-) T(reg) and CD4(+)CD25(-)CD127(+) conventional T cells (T(con)) were phenotypically analyzed for their constitutive as well as HMGB1-modulated expression of Toll-like receptors (TLR) and the receptor for advanced glycation end products (RAGE). Furthermore, the influence of recombinant and complexed HMGB1 from necrotic cell supernatant on the function of T(reg) and T(con) was investigated.
RESULTS: T(reg) express significantly higher levels of RAGE on the cell surface than T(con), while levels of TLR4 are similar. HMGB1 modulates T(reg) biology by inducing migration and prolonging survival. Furthermore, HMGB1 enhances IL-10 release and T(reg) suppressive capacity in a RAGE-dependent manner. In addition, HMGB1 directly suppresses IFNγ release of T(con) and inhibits their proliferation via TLR4.
CONCLUSION: HMGB1 directly enhances immune inhibitory functions of T(reg) via RAGE-mediated mechanisms and limits the number and activity of T(con). HMGB1 effects on T(reg) may alter immune reactivity in the setting of chronic inflammatory states such as cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22473704     DOI: 10.1093/intimm/dxs051

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  48 in total

Review 1.  DAMP-sensing receptors in sterile inflammation and inflammatory diseases.

Authors:  Tao Gong; Lei Liu; Wei Jiang; Rongbin Zhou
Journal:  Nat Rev Immunol       Date:  2019-09-26       Impact factor: 53.106

2.  High Mobility Group Protein 1 Reverses Immune System Paralysis in Late-Phase Sepsis.

Authors:  Qing-Yang Liu; Yue-Xin Wang; Zong-Sheng Wu; Zhen-Wei Shi; Xu Wu; Xin Chen; Zhao Yang; Kai-Zhi Xu
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

3.  Identification of tetranectin-targeting monoclonal antibodies to treat potentially lethal sepsis.

Authors:  Weiqiang Chen; Xiaoling Qiang; Yongjun Wang; Shu Zhu; Jianhua Li; Ariella Babaev; Huan Yang; Jonathan Gong; Lance Becker; Ping Wang; Kevin J Tracey; Haichao Wang
Journal:  Sci Transl Med       Date:  2020-04-15       Impact factor: 17.956

4.  Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression.

Authors:  Sujun Chen; Guanghui Zhu; Yue Yang; Fubo Wang; Yu-Tian Xiao; Na Zhang; Xiaojie Bian; Yasheng Zhu; Yongwei Yu; Fei Liu; Keqin Dong; Javier Mariscal; Yin Liu; Fraser Soares; Helen Loo Yau; Bo Zhang; Weidong Chen; Chao Wang; Dai Chen; Qinghua Guo; Zhengfang Yi; Mingyao Liu; Michael Fraser; Daniel D De Carvalho; Paul C Boutros; Dolores Di Vizio; Zhou Jiang; Theodorus van der Kwast; Alejandro Berlin; Song Wu; Jianhua Wang; Housheng Hansen He; Shancheng Ren
Journal:  Nat Cell Biol       Date:  2021-01-08       Impact factor: 28.824

5.  Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells.

Authors:  Y You; Y Li; M Li; M Lei; M Wu; Y Qu; Y Yuan; T Chen; H Jiang
Journal:  Clin Exp Immunol       Date:  2017-10-23       Impact factor: 4.330

Review 6.  Potential role of High mobility group box 1 in hepatocellular carcinoma.

Authors:  Rong-Rong Zhou; Xu-Yuan Kuang; Yan Huang; Ning Li; Ming-Xiang Zou; Dao-Lin Tang; Xue-Gong Fan
Journal:  Cell Adh Migr       Date:  2014       Impact factor: 3.405

7.  Life after death: targeting high mobility group box 1 in emergent cancer therapies.

Authors:  Z Sheng Guo; Zuqiang Liu; David L Bartlett; Daolin Tang; Michael T Lotze
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

8.  A role for HMGB1, HSP60 and Myd88 in growth of murine mammary carcinoma in vitro.

Authors:  Samantha A Chalmers; Alec S Eidelman; Jason C Ewer; Jacob M Ricca; Antonio Serrano; Kyle C Tucker; Caroline M Vail; Robert A Kurt
Journal:  Cell Immunol       Date:  2013-05-14       Impact factor: 4.868

9.  Post-traumatic immunosuppression is reversed by anti-coagulated salvaged blood transfusion: deductions from studying immune status after knee arthroplasty.

Authors:  N Islam; M Whitehouse; S Mehendale; M Hall; J Tierney; E O'Connell; A Blom; G Bannister; J Hinde; R Ceredig; B A Bradley
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

Review 10.  Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.

Authors:  Sherman S Leung; Josephine M Forbes; Danielle J Borg
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.